OBJECTIVES: Effective treatment of bleedings in hemophiliac patients is important for limiting costs associated with bleedings and for improving health outcomes. Two health outcomes of interest is the time from treatment initiation to bleeding resolution and the probability of developing re-bleedings. The objective of this study was to develop a methodology with NBF instead of the ICER for estimating the health economic benefits of a novel treatment with certain characteristics compared to rFVIIa and to identify the major determinants of the net monetary benefit of the novel treatment.   METHODS: Data from a medical chart review on hemophilia inhibitor patients in Turkey were used to identify predictors of the amount of rFVIIa used to achieve haemostasis. A Generalized Linear Regression Model was used to derive the potential cost-offsets of a novel treatment. The net monetary benefit per bleeding treated of the novel treatment compared to rFVIIa was estimated using a variety of assumptions on the efficacy of the novel treatment as well as on the valuation of the health benefits. RESULTS: Assuming a reduction in time to bleeding resolution by 25%, a novel treatment saved €339 per bleeding compared to rFVIIa. Including the value of the health benefits, which were estimated to €51, the net monetary benefit of the novel treatment was €390 per bleeding. The results were sensitive to assumptions around the efficacy of the new treatment but also around the valuation of health benefits. CONCLUSIONS: A novel treatment which reduces time to bleeding resolution would entail important health economic benefits, both in terms of health care cost-offsets and health benefits. One limitation of cost-effectiveness analyses in hemophilia is the uncertainty around the valuation of short term health benefits.